120 related articles for article (PubMed ID: 37258312)
41. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
[TBL] [Abstract][Full Text] [Related]
42. Values of debulking surgery for unresectable well-differentiated metastatic pancreatic neuroendocrine tumors: a comparative study.
Huang XT; Xie JZ; Chen LH; Cai JP; Chen W; Liang LJ; Zhang N; Yin XY
Gastroenterol Rep (Oxf); 2023; 11():goad010. PubMed ID: 36911142
[TBL] [Abstract][Full Text] [Related]
43. Number of Hepatic Resections and Association with Complication after Metastatic Neuroendocrine Tumor Debulking: An American College of Surgeons NSQIP Database Study.
Schwarz JL; Kuchta KM; Rojas A; Mehdi S; Hoon Choi S; Keutgen XM; Talamonti MS; Hogg ME
J Am Coll Surg; 2023 Jul; 237(1):157-168. PubMed ID: 37022773
[TBL] [Abstract][Full Text] [Related]
44. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
45. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
Keck KJ; Maxwell JE; Menda Y; Bellizzi A; Dillon J; O'Dorisio TM; Howe JR
Surgery; 2017 Jan; 161(1):272-279. PubMed ID: 27863780
[TBL] [Abstract][Full Text] [Related]
46. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
Wang SC; Parekh JR; Zuraek MB; Venook AP; Bergsland EK; Warren RS; Nakakura EK
Arch Surg; 2010 Mar; 145(3):276-80. PubMed ID: 20231629
[TBL] [Abstract][Full Text] [Related]
47. Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.
Woltering EA; Voros BA; Beyer DT; Wang YZ; Thiagarajan R; Ryan P; Wright A; Ramirez RA; Ricks MJ; Boudreaux JP
J Am Coll Surg; 2017 Apr; 224(4):434-447. PubMed ID: 28088602
[TBL] [Abstract][Full Text] [Related]
48. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation.
Bertani E; Fazio N; Radice D; Zardini C; Spinoglio G; Chiappa A; Ribero D; Biffi R; Partelli S; Falconi M
Eur J Surg Oncol; 2017 Feb; 43(2):372-379. PubMed ID: 27742480
[TBL] [Abstract][Full Text] [Related]
49. Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation.
Saxena A; Chua TC; Chu F; Al-Zahrani A; Morris DL
Am J Clin Oncol; 2012 Oct; 35(5):439-45. PubMed ID: 21654315
[TBL] [Abstract][Full Text] [Related]
50. Survival in patients with neuroendocrine tumors of the colon, rectum and small intestine.
Keller HR; Senapathi SH; Morada A; Bertsch D; Cagir B
Am J Surg; 2023 Jan; 225(1):58-65. PubMed ID: 36216612
[TBL] [Abstract][Full Text] [Related]
51. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
Seagle BL; Graves S; Strohl AE; Shahabi S
Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
[TBL] [Abstract][Full Text] [Related]
52. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
[TBL] [Abstract][Full Text] [Related]
53. Debulking Surgery for Moderately Differentiated Neuroendocrine Gastric Carcinoma - A Case Report and Literature Review.
Bacalbasa N; Halmaciu I; Bolca C; Neacsu A; Cretoiu D; Balalau C; Diaconu C; Iliescu L; Filipescu A; Pop C; Balescu I
In Vivo; 2020; 34(3):1527-1531. PubMed ID: 32354958
[TBL] [Abstract][Full Text] [Related]
54. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery.
Eoh KJ; Lee JY; Yoon JW; Nam EJ; Kim S; Kim SW; Kim YT
Oncotarget; 2017 Jun; 8(23):37807-37816. PubMed ID: 27906676
[TBL] [Abstract][Full Text] [Related]
55. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study.
Le Treut YP; Grégoire E; Klempnauer J; Belghiti J; Jouve E; Lerut J; Castaing D; Soubrane O; Boillot O; Mantion G; Homayounfar K; Bustamante M; Azoulay D; Wolf P; Krawczyk M; Pascher A; Suc B; Chiche L; de Urbina JO; Mejzlik V; Pascual M; Lodge JP; Gruttadauria S; Paye F; Pruvot FR; Thorban S; Foss A; Adam R;
Ann Surg; 2013 May; 257(5):807-15. PubMed ID: 23532105
[TBL] [Abstract][Full Text] [Related]
56. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
57. Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness.
Huang T; Qi H; Shen L; Wu Y; Song Z; Cao F; Liu Y; Xie L; Chen S; Tang T; Li H; Zhang Y; Feng L; Zhang H; Chen J; Fan W
Int J Hyperthermia; 2022; 39(1):935-945. PubMed ID: 35853727
[TBL] [Abstract][Full Text] [Related]
58. Ultrasound-guided percutaneous radiofrequency ablation in treatment of neuroendocrine tumor liver metastases：a single-center experience.
Huang J; Liu B; Lin M; Zhang X; Zheng Y; Xie X; Xu M; Xie X
Int J Hyperthermia; 2022; 39(1):497-503. PubMed ID: 35285400
[TBL] [Abstract][Full Text] [Related]
59. How good are the outcomes of instrumented debulking operations for symptomatic spinal metastases and how long do they stand? A subgroup analysis in the global spine tumor study group database.
Depreitere B; Ricciardi F; Arts M; Balabaud L; Bunger C; Buchowski JM; Chung CK; Coppes MH; Fehlings MG; Kawahara N; Martin-Benlloch JA; Massicotte EM; Mazel C; Meyer B; Oner FC; Peul W; Quraishi N; Tokuhashi Y; Tomita K; Verlaan JJ; Wang M; Crockard HA; Choi D
Acta Neurochir (Wien); 2020 Apr; 162(4):943-950. PubMed ID: 31953690
[TBL] [Abstract][Full Text] [Related]
60. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
